Comparison of intestinal histopathological changes&#160;following teclistamab, BCMA-directed CAR T, CD19-directed CAR T and rituximab therapies.

Rituxan (rituximab) - Roche

Tecvayli (teclistamab-cqyv) - Genmab, J&J

http://www.ncbi.nlm.nih.gov/pubmed/42732998

Don Siegel; Esther Baranov; Isairis Peralta Valerio; Kristen M Stashek; Natalie Respond; Olivia J Leung; Pooja Devi; Robin Collingwood

Sep 14, 2026